Observational Cross-reactivity Study for Colorectal Cancer Diagnosis

Launched by ADVANCED MARKER DISCOVERY S.L. · Mar 20, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a blood test designed to help diagnose colorectal cancer. The main goal is to find out how often this test might incorrectly suggest that someone has cancer when they actually do not, which is known as the false positive rate. To do this, researchers will enroll 250 patients who have been diagnosed with various types of cancer or gastrointestinal diseases, but not colorectal cancer itself. Participants will provide a blood sample during their regular medical care and share information about their health risks.

To be eligible for this study, participants must be at least 18 years old and should not have had prior treatments like chemotherapy or surgery for their cancer. Additionally, they should not have a history of certain colorectal conditions, such as colorectal cancer or specific growths in the colon. If you choose to participate, you’ll be contributing valuable information to help improve cancer diagnosis methods while receiving routine care. This study is currently recruiting participants of all genders, and taking part could help shape future tests for colorectal cancer diagnosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients older than 18 years of age at the time of blood sample collection.
• • Subjects must be able to understand the information provided on the participant information sheet, must consent to participate in the study, and must sign the informed consent form.
• • Patients diagnosed with only one type of cancer (no colorectal cacner) or gastrointestinal disease.
• Exclusion Criteria:
• • Patients who have received previous chemotherapy or radiotherapy.
• • In case of diagnosis of a tumor: patients who have undergone total or partial surgical resection of the tumor.
• • Patients with a personal history of advanced or non-advanced colorectal adenoma, serrated lesions, colorectal cancer, familial adenomatous polyposis or Lynch syndrome.
• • Patients without appropriate staging or diagnosis.
• • Patients with hemolyzed plasma.